Nicolás Merchante1, Manuel Parra-Sánchez1, Antonio Rivero-Juárez2, Celia Cifuentes1, Ángela Camacho2, Juan Macías1, Loreto Martínez-Dueñas2, Elisabet Pérez-Navarro1, Antonio Rivero2, Juan A Pineda3. 1. Unidad de Enfermedades Infecciosas y Microbiología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Sevilla, Spain. 2. Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain. 3. Unidad de Enfermedades Infecciosas y Microbiología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Sevilla, Spain. Electronic address: japineda@telefonica.net.
Abstract
OBJECTIVE: To look for evidence of hepatitis E virus (HEV) exposure in HIV-infected patients with unexplained elevations of liver stiffness (LS). METHODS: Case-control study conducted in 31 HIV-infected patients with unexplained elevations of LS and in 31 HIV-controls with normal LS, matched by age, sex and CD4 cell-counts. Serum HEV antibodies were tested by two ELISA procedures and by Immunoblot. We defined exposure to HEV as the detection of serum HEV antibodies by at least one of the two ELISA assays, provided that it was confirmed by Immunoblot. A real-time PCR RNA assay was conducted in all plasma samples to identify subjects with active HEV infection. RESULTS: Exposure to HEV was demonstrated, according to the criteria used in this study, in 9 (29%) of the cases, whereas it was shown in 5 (16%) of the controls (p=.3). Serum HEV RNA was detected in none of the controls and in only in one case. This patient had a documented chronic hepatitis E with progression to cirrhosis. CONCLUSIONS: HEV antibodies are frequently found in HIV-infected patients with unexplained liver disease.
OBJECTIVE: To look for evidence of hepatitis E virus (HEV) exposure in HIV-infectedpatients with unexplained elevations of liver stiffness (LS). METHODS: Case-control study conducted in 31 HIV-infectedpatients with unexplained elevations of LS and in 31 HIV-controls with normal LS, matched by age, sex and CD4 cell-counts. Serum HEV antibodies were tested by two ELISA procedures and by Immunoblot. We defined exposure to HEV as the detection of serum HEV antibodies by at least one of the two ELISA assays, provided that it was confirmed by Immunoblot. A real-time PCR RNA assay was conducted in all plasma samples to identify subjects with active HEV infection. RESULTS: Exposure to HEV was demonstrated, according to the criteria used in this study, in 9 (29%) of the cases, whereas it was shown in 5 (16%) of the controls (p=.3). Serum HEV RNA was detected in none of the controls and in only in one case. This patient had a documented chronic hepatitis E with progression to cirrhosis. CONCLUSIONS:HEV antibodies are frequently found in HIV-infectedpatients with unexplained liver disease.
Authors: N W Furukawa; E H Teshale; L Cosmas; M Ochieng; S Gikunju; B S Fields; J M Montgomery Journal: J Clin Virol Date: 2016-02-23 Impact factor: 3.168
Authors: Jose D Debes; Suzan D Pas; Zwier M A Groothuismink; Marchina E van der Ende; Robert A de Man; Andre Boonstra Journal: Liver Int Date: 2018-01-19 Impact factor: 5.828